Exome Asset Management’s Immunic IMUX Stock Holding History

Exome Asset Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,390	Closed	-$153K	–	73
2025 Q3	$153K	Buy	+17,390	New	+$153K	0.09%	67

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Exome Asset Management's IMUX Position: Q4 2025 in Review

Exome Asset Management sold out of Immunic (IMUX) in Q4 2025, closing a stake of 17,390 shares — an estimated $153K sold.

Exome Asset Management first reported a position in IMUX in Q3 2025 and held it in 1 quarter. The position peaked at $153K in Q3 2025. 58 funds tracked by Wall St. Rank hold IMUX as of Q4 2025.

Exome Asset Management reported no remaining Immunic position as of Q4 2025 after selling out during the quarter.
Exome Asset Management sold 17,390 Immunic shares in Q4 2025, an estimated $153K.
Exome Asset Management first reported a position in Immunic in Q3 2025 and held it in 1 quarter.
Exome Asset Management's Immunic position peaked at $153K in Q3 2025.
58 funds tracked by Wall St. Rank held Immunic as of Q4 2025.

Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.